论文部分内容阅读
目的观察经导管动脉内化疗栓塞(TACE)联合射频消融(RFA)治疗原发性肝癌的临床疗效。方法将220例原发性肝癌患者随机分为观察组和对照组各110例。观察组采取TACE联合RFA治疗,对照组仅采取TACE治疗。跟踪随访3年,观察2组临床效果,对比2组生存率。结果观察组肿瘤完全灭活率明显高于对照组,差异有统计学意义(P<0.05)。术后对患者进行为期1~3年的跟踪随访,观察组3年生存率明显高于对照组,差异均有统计学意义(P<0.05)。结论 TACE联合RFA治疗原发性肝癌效果确切,且优于单纯采用TACE治疗。
Objective To observe the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of primary liver cancer. Methods 220 patients with primary liver cancer were randomly divided into observation group and control group of 110 cases. The observation group was treated with TACE combined with RFA, while the control group was treated with TACE only. The patients were followed up for 3 years and the clinical effects of 2 groups were observed. The survival rates of 2 groups were compared. Results The complete tumor inactivation rate in the observation group was significantly higher than that in the control group (P <0.05). The patients were followed up for 1 to 3 years after operation. The 3-year survival rate of the observation group was significantly higher than that of the control group (P <0.05). Conclusion The combination of TACE and RFA for the treatment of primary liver cancer is more effective than TACE alone.